This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): CNTO 1275, ustekinumab
Description: Ustekinumab is a human monoclonal antibody that targets interleukin-12 and interleukin-23, proteins that occur naturally in the immune system.
Deal Structure: Ustekinumab was developed using Medarex's UltiMAb Human Antibody Development System. In May 2000, Medarex signed a broad antibody development agreement with Centocor, a wholly owned subsidiary of Johnson & Johnson. This agreement allows Centocor and other affiliates of Johnson & Johnson to access the Medarex HuMAb-Mouse technology for an unlimited number of targets. Under the terms of the agreement, Medarex will receive technology access fees, and could also receive license fees, milestone fees and royalties on product sales.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
In September 2009, Bristol-Myers Squibb completed its acquisition of Medarex.
On an undisclosed date, DRI Capital purchased royalties relating to the sales of Stelara for plaque psoriasis and psoriatic arthritis. As a...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company DRI Capital Inc.
Additional information available to subscribers only: